Harmonisation Group

Chair and Co-Chair: Andy Rawstron (Great Britain) and  Jan W. Gratama (The Netherlands)

Committee Members: formed from lead participants in individual projects

Aim: To develop working groups that identify, validate and publish consensus approaches for clinical diagnostic cytometry. 
 
The European Working Group for Clinical Cell Analysis was founded in 1996 to develop consensus in clinical cytometry and ESCCA continues this effort in the harmonisation committee. Andy has been involved in more than 15 consensus projects over the past two decades, in collaboration with several international groups including ICCS, Euroflow, EMN, and ERIC. 
The ESCCA harmonisation group identifies relevant topics by survey of the members to determine the most pressing requirements for harmonisation and validation. Based on the experience of many different consensus project, the proposed approach for subsequent harmonisation projects is as follows: 
1) Develop laboratory and clinical working groups for specific diagnostic topics
2) Survey members to identify consensus on required (for all resource settings) vs. recommended markers for diagnosis / monitoring
3) Identify positive and negative controls, preferably in normal peripheral blood, and calculate an appropriate relative signal on the control populations that can be used to specify appropriate reagents
4) Define a consensus approach and test this retrospectively if possible. Confirm the consensus after consultation with members and publish. 
5) Test the consensus approach prospectively and identify diagnostic challenges
 
The ESCCA harmonisation group has successfully completed two consensus projects so far: 
1.“The Flow Cytometric Detection of Minimal Residual Disease”. Published in collaboration with the ICCS in January 2016, Cytometry B Special Issue. Volume 90 pages 1-100. 
2.“Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project”. "The consensus document has been submitted to Clinical Cytometry and revisions have been requested. The originally submitted version can be viewed [pdflink to paper735.33 KB]. It may be possible to make minor amendments prior to re-submission so please send any comments on the paper to "andy.rawstron@ecsg.york.ac.uk".
3. "Prospective validation of flow cytometry panels for CLL diagnosis and MRD".  Many thanks to all the people who submitted responses to the survey on the type of panels that they would like to assess prospectively for CLL diagnosis and monitoring. A summary of the responses can be viewed [pdflink to survey1.3 MB] and we will update in the near future with a proposal to undertake prospective validation based on the response."

 

Immunodeficiency Working Group

Chair: Ulrich Sack (Germany)

Committee Members: Gulderen Demirel (Turkey), Claude Lambert (France), Mohammad Ibrahim (USA), 

Aim: ESCCA Working Group on Immunodeficiencies intends to strengthen research and clinical application of flow cytometry in Clinical Immunology. The target is to establish, to improve, and to harmonize approaches for immunodeficiency detection, monitoring, and treatment. To do so, WG-ID will:

  • analyze need for ID screening in clinical practice
  • review panels, guidelines, and proposals as published
  • co-operate with national and international (IFCC) scientific organizations
  • interact with EQA providers
  • propose optimized panels
  • contribute to training and education
  • publish papers in the field of clinical cytometry for immunodeficiencies
  • contribute to the ESCCA web page